Henri Huezo

Development of purine-scaffold small molecule inhibitors of Hsp90.

N. Rosen, D. Solit, G. Chiosis, 2003, Current cancer drug targets.

Development of a Fluorescence Polarization Assay for the Molecular Chaperone Hsp90

N. Rosen, G. Chiosis, S. Felts, 2004, Journal of biomolecular screening.

Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.

N. Rosen, G. Chiosis, S. Felts, 2003, Bioorganic & medicinal chemistry letters.

17 AAG : Low Target Binding Affinity and Potent Cell Activity — Finding an Explanation 1

N. Rosen, L. Neckers, G. Chiosis, 2003 .

Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.

N. Rosen, D. Solit, G. Chiosis, 2004, Chemistry & biology.

Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.

N. Rosen, G. Chiosis, A. Shtil, 2002, Bioorganic & medicinal chemistry.

17AAG: low target binding affinity and potent cell activity--finding an explanation.

N. Rosen, L. Neckers, G. Chiosis, 2003, Molecular cancer therapeutics.

Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR.

N. Rosen, G. Chiosis, M. Vilenchik, 2003, Chemistry & biology.